This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Adverse Events
Timeframe: Through study completion, 43 days
Vital Signs
Timeframe: Through study completion, 43 days
Laboratory Tests
Timeframe: Through study completion, 43 days
Glucose nadir after dosing
Timeframe: 0-3 hours following liquid meal